Spain and Greece IVF Tourism Soars as Fertility Travellers Discover New European Options

Written By: Sarannya Acharya

Sarannya Acharya

Sarannya Acharya is a content writer with a strong academic and professional background in media and communication. She holds an M.Sc in Media Science and is currently pursuing a Ph.D. at Swami Vivekananda University, Barrackpore, with a specialization in Advertising. With over three years of experience in content writing, she brings a blend of research-driven insight and creative storytelling to her work. Alongside her professional role, she is actively engaged in academics, contributing to the field through teaching and scholarly involvement. Her expertise lies in crafting well-structured, engaging, and informative content, supported by a solid foundation in media theory and practical industry knowledge.

See Full Bio

August 23, 2026 23:16 GMT+5:30

Image generated with Ai

Spain and Greece IVF Tourism is gaining attention as fertility travellers explore new European options for specialised care. Increasingly, Spain and Greece IVF Tourism connects medical journeys with international travel, giving fertility travellers more destinations to consider. Moreover, Spain and Greece IVF Tourism reflects the growing global interest in regulated reproductive healthcare and cross-border treatment. For travellers, however, choosing Spain or Greece requires careful research into medical requirements, regulations, clinic credentials, visas and treatment schedules. Therefore, Travel And Tour World urges readers to read the entire story before considering these European options, as fertility travellers need reliable information before planning Spain and Greece IVF Tourism journeys.

Spain and Greece Become Important Names in Fertility Travel

Spain and Greece are attracting growing attention in international medical tourism, particularly among people researching IVF and assisted reproduction overseas. The trend highlighted in the referenced report is especially relevant for American patients considering treatment outside the United States.

However, travellers should view fertility tourism differently from ordinary holidays. Treatment decisions involve medical assessments, legal requirements, clinic authorisation, travel documentation and potentially several appointments.

Official Spanish and Greek sources confirm that both countries maintain formal regulatory systems for assisted reproduction.

Spain Has a National IVF Regulatory Framework

Spain regulates assisted human reproduction through Law 14/2006. The legislation states that women over 18 with full legal capacity can access regulated assisted-reproduction techniques after providing free, informed and express written consent. The law also says access is not dependent on marital status or sexual orientation.

Spain also maintains a national registry of reproductive-health centres and services. The official database allows patients to examine facilities, their authorised services, inspections and authorisation periods.

The registry demonstrates the breadth of Spain’s regulated fertility infrastructure. Listed facilities can include services such as IVF, artificial insemination, oocyte banks, sperm banks, embryo banks and oocyte-recovery units.

Spain additionally maintains national registers covering donors and treatment activity and results. The Health Ministry says a national activity-and-results registry operates under the framework established by Law 14/2006.

Greece Offers Another Regulated European Option

Greece has its own National Authority for Medically Assisted Reproduction. The authority oversees important regulatory aspects of assisted reproduction and publishes relevant legislation and official decisions.

A major change came through Law 4958/2022. Under the updated framework, assisted reproduction for women is permitted up to 54 years and zero days. Women aged from 50 years and one day through 54 require specific authorisation from the national authority.

The approval process can require medical documentation. Official guidance says applicants in the 50-to-54 age group need relevant medical opinions before authorisation is granted. The approval can remain valid for one year, subject to the statutory age limit.

Greece also maintains controls concerning reproductive-material donation. Its authority states that sperm donors must generally be under 40, while egg donors must generally be under 35, with limited exceptions authorised under the applicable framework. Donors undergo required clinical and laboratory screening.

International Patients Must Understand the Travel Rules

For travellers, treatment eligibility is only one part of the journey.

Spain’s official consular guidance confirms that a Schengen visa can cover medical treatment for stays of up to 90 days within a 180-day period for eligible third-country nationals.

Visa applicants may need evidence explaining the purpose and conditions of their stay, sufficient financial resources and their intention to leave before visa expiry.

Travel medical insurance is also important. Spanish consular guidance requires qualifying applicants to have coverage for emergency healthcare, hospital treatment and medical repatriation, with minimum coverage of €30,000.

What Fertility Travellers Should Check Before Departure

Patients considering IVF abroad should verify the treatment provider through official registers wherever available.

They should ask clinics about treatment timelines, required consultations, laboratory procedures and follow-up arrangements.

Flight and accommodation planning should remain flexible because medical schedules can change.

Travellers should also investigate visa requirements based on nationality. Spain’s official guidance makes clear that medical-treatment travel still requires compliance with Schengen entry conditions.

Most importantly, patients should obtain individual medical and legal advice before committing to treatment overseas.

Medical Travel Requires More Than a Flight

Spain and Greece offer established regulatory frameworks that make them significant destinations in Europe’s fertility-tourism conversation.

For global travellers, their appeal is not simply connected to tourism. Their healthcare regulations, authorised facilities and international accessibility can influence treatment planning.

Yet IVF travel should never be approached like a conventional holiday. Medical suitability, legal eligibility, provider authorisation, insurance, documentation and continuity of care should come first.

For international patients exploring fertility options in 2026, Spain and Greece therefore represent two European destinations worth researching carefully through official government information and qualified medical professionals.

Global IVF Medical Tourism: The World’s Leading Fertility Travel Destinations, Tourism Scale and Medical Travel Data

International fertility travel is becoming an increasingly visible part of the wider medical-tourism industry. However, one important statistical limitation must be clear: most governments do not publish a separate percentage for IVF tourists. They usually record general tourism and, in some countries, medical-purpose arrivals. IVF is often grouped with broader reproductive or healthcare services.

The table below therefore separates verified tourism figures, medical-tourism figures where officially available, and IVF/ART indicators. IVF percentages should not be invented where governments do not publish them.

Spain: Europe’s Major IVF and Tourism Powerhouse

Spain combines enormous tourism volume with one of Europe’s largest assisted-reproduction markets. The country welcomed 96.8 million international tourists in 2025, a record and a 3.2% increase from 2024. International visitors spent €134.712 billion, up 6.8%. Spain also reported about 114,000 ART cycles in 2020, according to the European Society of Human Reproduction and Embryology. ESHRE says Europe collectively reported 923,318 treatment cycles that year, representing roughly half of reported global ART activity. For fertility travellers, Spain’s advantage is therefore not simply tourism scale. It has an established assisted-reproduction regulatory framework and a national registry of reproductive-health centres. The important caveat is that Spain does not publish an official percentage showing what share of its 96.8 million tourists travelled specifically for IVF. Travellers should therefore treat clinic-level claims about international IVF patients separately from national tourism statistics.

Greece: High ART Availability Meets Mediterranean Tourism

Greece is another important European fertility-travel destination. Bank of Greece data show 43.31 million inbound travellers in 2025, representing a 6.4% increase from 2024. The country generated €20.647 billion in travel receipts, although receipts specifically from health-purpose trips declined 34.9% to €19.9 million. Greece recorded approximately 111,000 ART cycles in 2020, according to ESHRE. Greece, alongside Czechia and Estonia, was among Europe’s countries with the highest ART availability, exceeding 2,900 cycles per million inhabitants. ESHRE also reported that more than 5% of babies born in Greece were conceived through ART in its cited dataset. This creates an unusual combination for travellers: a large international tourism ecosystem and substantial assisted-reproduction activity. Yet Greece’s official tourism statistics do not provide a separate national percentage for IVF travellers, meaning claims about IVF-tourism market share require caution.

Czechia: A Smaller Tourism Market With Strong Fertility Capacity

Czechia is less dependent on mass tourism than Spain or Greece, but its fertility infrastructure gives it importance in European medical travel. ESHRE places Czechia among the European countries with more than 2,900 ART cycles per million inhabitants, one of the highest availability levels reported. It also states that more than 5% of births in Czechia were conceived through ART in the relevant European dataset. Czechia’s broader tourism statistics should not automatically be interpreted as medical-tourism figures. Likewise, there is no reliable government-published percentage identifying IVF visitors as a proportion of all foreign tourists. For travellers, this distinction is crucial. A destination can have a highly developed fertility sector without having a separately measured IVF-tourism industry.

India: Medical Travel Is a Measurable Part of International Tourism

India provides one of the clearest examples of medical tourism being measured separately. Government data show 20.57 million international tourist arrivals in 2024, while Foreign Tourist Arrivals reached 9.95 million. The Ministry of Tourism reported 625,000 foreign tourist arrivals for medical purposes in 2024, compared with 659,000 in 2023. Using FTAs as the denominator, medical-purpose arrivals represented approximately 6.28% of foreign tourist arrivals in 2024. India also operates an official Medical Value Travel portal and provides e-medical and e-medical-attendant visas for nationals of 167 countries. However, India’s government does not publish an IVF-specific international-patient percentage. Therefore, IVF should be viewed as one component of the broader medical-value-travel market rather than assigned an unsupported national share.

Thailand: IVF Travel Fits Into a Large Asian Medical Hub

Thailand welcomed 35,047,501 international visitors in 2024, generating more than 1.8 trillion baht in tourism revenue. The country’s connectivity also expanded significantly, with airline seat capacity reaching about 47 million seats in 2024, a 26% increase from 2023. Thailand has specifically studied foreign visitors seeking infertility treatment. A Thai government health-services study identified China, Vietnam, Myanmar, India, Hong Kong, Indonesia, Cambodia, Japan, Laos and Singapore among the leading markets for IVF-related medical visitors. The study also reported an average stay of approximately five days and medical-service expenditure ranging from 234,923 to 700,000 baht per person in the surveyed data. These figures demonstrate that fertility treatment has a measurable international component, although they should not be presented as a current national IVF-tourism percentage.

Türkiye: Medical Tourism Has Reached More Than 1.5 Million Visitors

Türkiye has developed one of the world’s largest medical-tourism ecosystems. Government tourism information states that the country received 62.3 million visitors in 2024, generating $61.1 billion in tourism revenue. Separate Turkish government promotional material reports that more than 1.5 million people travelled to Türkiye for medical tourism in 2024, producing more than $3 billion in revenue. If the 1.5 million medical travellers are compared with 62.3 million total visitors, medical tourism represented roughly 2.4% of the visitor figure. This is an approximate comparison because the two datasets may use different definitions and counting methods. Türkiye does not publish a comparable nationwide percentage specifically for IVF travellers. For fertility tourists, its importance therefore comes from the broader scale of its internationally oriented healthcare sector.

Malaysia: Southeast Asia’s Healthcare Travel Gateway

Malaysia is another destination where medical travel and conventional tourism operate side by side. Tourism Malaysia recorded 25,016,698 tourist arrivals in 2024, up 24.2% from 2023. Total visitor arrivals, including tourists and excursionists, reached 37,961,485, up 31.1%. India supplied more than 1.13 million tourist arrivals, while China contributed more than 3.28 million. Malaysia’s healthcare-travel authorities actively promote the country as a regional medical destination, particularly for Asian patients. However, neither national tourism statistics nor the available government material provides a dependable percentage specifically for IVF visitors. Consequently, Malaysia should be considered a broader medical-travel destination where fertility services form part of a larger healthcare ecosystem.

What the Global Numbers Really Mean for IVF Travellers

The international data reveal a major measurement problem. Regular tourism is usually counted comprehensively, medical tourism is measured inconsistently, and IVF tourism is rarely isolated in national statistics.

Europe remains particularly important for ART. ESHRE reports that more than 3 million ART cycles are now reported worldwide annually, with registry data estimated to capture about 75% of all treatment. It therefore estimates roughly 4 million cycles annually worldwide, with approximately 1 million babies born through ART.

For travellers, these figures provide useful context but should not replace medical research. Prospective patients should verify clinic authorisation, treatment eligibility, national fertility laws, visa requirements, insurance and follow-up arrangements before travelling.

The most important lesson is simple: a country’s popularity as a tourist destination does not automatically prove that it is the right IVF destination for an individual patient. Medical suitability, regulation and continuity of care should remain the deciding factors.

Conclusion

Spain and Greece are emerging as important names in global IVF tourism, giving fertility travellers new European options to consider. Moreover, both destinations combine established healthcare systems with strong international travel connections. However, treatment abroad requires careful planning, from checking clinic credentials and medical eligibility to understanding regulations, visas and follow-up care. Therefore, travellers should research official government guidance and consult qualified medical professionals before making decisions. As fertility travel continues to evolve, Spain and Greece could attract greater international attention. Travel And Tour World encourages readers to consider the opportunities carefully while keeping safety, legality and individual medical needs at the centre of every journey.